

# **Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study**

Chang-Fu Kuo,<sup>1,2</sup> Matthew J. Grainge,<sup>3</sup> Christian Mallen<sup>4</sup>, Weiya Zhang,<sup>1#\*</sup> Michael Doherty<sup>1#</sup>

Author affiliations:

1. Division of Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, UK

2. Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

3. Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, UK

4. Arthritis Research UK Primary Care Centre, Keele University, Keele, UK

Word count: 3,759

Joint senior authors: Dr Weiya Zhang and Dr Michael Doherty

Corresponding author: Dr Weiya Zhang

Email: [weiya.zhang@nottingham.ac.uk](mailto:weiya.zhang@nottingham.ac.uk)

Address: Academic Rheumatology, Clinical Sciences Building, City Hospital, Nottingham, United Kingdom

NG51PB

Telephone: +44 (0) 115 8231756

## Abstract

**Objectives.** To describe trends in the epidemiology of gout and patterns of urate-lowering treatment (ULT) in the UK general population from 1997-2012.

**Methods.** We used the Clinical Practice Research Datalink (CPRD) to estimate the prevalence and incidence of gout for each calendar year from 1997 to 2012. We also investigated the pattern of gout management for both prevalent and incident gout patients.

**Results.** In 2012, the prevalence of gout was 2.49% (95% CI, 2.48%–2.51%) and the incidence was 1.77 (95% CI, 1.73–1.81) per 1,000 person-years. Prevalence and incidence both were significantly higher in 2012 than in 1997, with a 63.9% increase in prevalence and 29.6% increase in incidence over this period. Regions with highest prevalence and incidence were the North East and Wales. Among prevalent gout patients in 2012, only 48.48% (95% CI, 48.08%–48.89%) were being consulted specifically for gout or treated by ULT and of these 37.63% (95% CI, 37.28%–38.99%) received ULT. In addition, only 18.6% (95% CI, 17.6%–19.6%) of incident gout patients received ULT within 6 months and 27.3% (95% CI, 26.1%–28.5%) within 12 months of diagnosis. The management of prevalent and incident gout patients remained essentially the same during the study period, although the percentage of adherent patients improved from 28.28% (95% CI, 27.33%–29.26%) in 1997 to 39.66% (95% CI, 39.11%–40.22%) in 2012.

**Conclusions.** In recent years both the prevalence and incidence of gout have increased significantly in the UK. Suboptimal use of ULT has not changed between 1997 and 2012. Patient adherence has improved during the study period, but it remains poor.

**Funding:** University of Nottingham and Chang Gung Memorial Hospital

**Keywords:** gout, prevalence, incidence, urate-lowering treatment, adherence

## Introduction

Gout is the most common inflammatory arthritis with a diverse spectrum of clinical manifestations. In addition to recurrent acute arthritis, subcutaneous tophi and chronic painful arthritis,[1] it also has an impact on morbidity[2-4] and premature mortality.[5-7] Gout results from the deposition of monosodium urate (MSU) crystal in peripheral joints and soft tissues due to persistent elevation of uric acid levels above the saturation point for crystal deposition. Effective urate-lowering treatment (ULT) that maintains uric acid below this critical level will prevent further MSU crystal formation and dissolve away existing crystals,[8] making gout the only chronic arthritis that can be 'cured'. However, studies show that only a minority of gout patients receive effective treatment, the majority continuing to experience recurrent acute attacks, further joint damage and other complications.[9-12]

In the United Kingdom, several studies have estimated the prevalence of gout since the 1970's.[13-20] Two of these both report a prevalence of 1.4% onward from 1999[18] to 2005[19] suggesting a plateau of prevalence, whereas three studies using different population-based databases have reported a rise in the incidence of gout in the past decade.[18, 20, 21] In addition, only approximately a quarter of gout patients in the UK receive ULT within one year from diagnosis,[21] which should contribute substantially to the elevated prevalence.

Currently, UK data from the current millennium exploring gout incidence and prevalence, assessed at multiple time points in the same population, are sparse. Therefore, we undertook this study to examine the prevalence and incidence of gout and patterns of gout management using the Clinical Practice Research Datalink (CPRD) from 1997-2012.



## **Methods**

The study was approved by the Trent Multi-centre Research Ethics Committee (reference number: 05/MRE04/87) and the Independent Scientific Advisory Committee (11-021R).

### **Source of data**

The Clinical Practice Research Datalink (CPRD) is one of the largest databases of longitudinal medical records from primary care in the world. Established in 1987 and named the General Practice Research Database (GPRD) until April 2012, the CPRD has collected anonymised clinical records from around 12 million individuals, representing 8% of the UK population, with demonstrated reliable research standard data. A recent systematic review supported a high validity of recorded diagnoses in CPRD, with a median proportion of cases with a confirmed diagnosis of 89% for 183 different conditions.[22]

### **Study population**

Our study comprised all participants who contributed data to the CPRD between 1<sup>st</sup> January 1997 and 31<sup>st</sup> December 2012. The denominator for prevalence estimation (eligible population) for each calendar year included all individuals registered on 1<sup>st</sup> July of each calendar year with the general practices which were up-to-standard for CPRD research. For incidence of gout we constructed at-risk cohorts for each calendar year which comprised all individuals registered with up-to-standard practices during the year specified who had no history of gout diagnosis before the latest of current registration date plus 365 days or 1<sup>st</sup> Jan of the calendar year specified. Person-years of follow-up were then calculated from the latest of 1<sup>st</sup> Jan or the date of registration plus 365 days to the earliest date of transfer-out, incident

gout diagnosis, death or 31<sup>st</sup> December of the specified year.

### **Case definition of gout**

Prevalent cases of gout were defined as participants who had gout on 1<sup>st</sup> July of each calendar year, whereas incident cases of gout were those who had no gout prior to the latest of current registration date plus 365 days or 1<sup>st</sup> January of each calendar year but developed gout during the year were defined as incident cases of gout. To be eligible as an incident case, participants had to have at least one-year registration prior to the first date of gout diagnosis.[21] Gout was defined as according to READ coding. Since some READ codes apparently indicate prevalent gout (such as history of gout), we only used 18 codes for incident gout identification but there were 39 codes for prevalent gout identification (see supplementary table 1). The case definition has been validated in a previous study.[23] Meier et al reviewed medical records and laboratory results of 10 confirmed (with recorded diagnosis, elevated serum urate and drug treatment) and 28 probable (with recorded diagnoses and drug treatment) gout patients and ascertained 10 out of 10 confirmed cases and 24 out of probable cases to be true gout patients (overall positive predictive value 90%).

### **Estimation of prevalence and incidence**

Prevalence was calculated using the number of people diagnosed with gout at any time before the mid-point of a calendar year as the numerator and the number of all individuals contributing CPRD data at the same time point as the denominator. Incidence was calculated using the number of incident gout cases during a calendar year as the numerator and the total person-years occurring during the same year as the denominator.



Prevalence and incidence were calculated for 13 regions in the UK: North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, South West, South Central, London, South East Coast, Northern Ireland, Scotland, and Wales. To remove the effect of different age and gender structures in these regions, we standardised prevalence and incidence with the overall population structure using 2012 as the reference. We used choropleth maps to represent geographic variations of gout in the UK.

### **Pattern of treatment**

We studied the proportion of prevalent gout patients who were being consulted specifically for gout or being treated by ULT (allopurinol, febuxostat, benzbromarone, probenecid or sulfapyrazone) in each calendar year during the period 1997-2012. We also estimated the proportion of incident patients who were treated by ULT within 6 months and 12 months of diagnosis.

### **Adherence to ULT**

Adherence of ULT among prevalent gout patients was measured using proportion of days covered (PDC) to represent the degree of prescription-filling in a given interval specified. PDC was calculated as the proportion of days on which a patient had available prescriptions for ULT in each interval, which was defined as the period from the latest of registration date or 1<sup>st</sup> Jan to the earliest of transfer-out, death date or 31 Dec of the calendar year specified. For overlapping prescriptions, the later prescription was assumed to start from the end of the prior prescription; this was to avoid double counting of days covered. We then divided the gout patients into 4 groups according to status of being treated and adherence at each calendar year: not treated, non-adherent (those with a PDC less than 20%), partially adherent

(those with a PDC of 20% to 79%) and adherent (those with a PDC of at least 80%). We assessed the management of incident gout patients by the percentage of incident gout patients treated with ULT at 6 months and one year after diagnosis.

### **Trends of prevalence, incidence and management of gout**

To determine the trends of prevalence, incidence and management of gout, we calculated age-, sex- and length of data contribution-standardised prevalence, incidence of gout and pattern of ULT in each calendar year from 1997 to 2012 with the population structure in year 2012 as reference. The length of data contribution of each patient was defined as the period from the current date of registration to 1<sup>st</sup> July of each calendar year for prevalence, or to 1<sup>st</sup> Jan of the calendar year specified for incidence. The reasons to include length of data contribution to standardise prevalence, incidence and PDC were (1) prevalence, incidence and PDC estimation were subject to length of data contribution with a tendency toward higher prevalence and incidence (supplementary figure 1) and (2) the distribution of length of data contribution was different in calendar years studied, with longer length of data contribution in more recent years (supplementary figure 2).

### **Statistical analysis**

The 95% confidence intervals (CIs) for prevalence and incidence were derived on the basis of the assumption of a Poisson distribution of the observed prevalent cases. We used the Joinpoint Regression Program (version 4.0.4) to estimate trends of prevalence and incidence of gout. The program uses Bayesian Information Criterion to generate different numbers of 'join points' in time when the trend of prevalence and incidence of gout change significantly and to determine the best-fit data series.[24] Initially models contained zero joinpoints (i.e. a

straight line fitted to the data) with joinpoints added whenever a change in trend over time is statistically significant, with the user specifying the maximum number of allowable joinpoints. Using a Bayesian information criterion approach, we selected maximum of three joinpoints. Annual percentage changes (APC) for each segment and average annual percentage changes (AAPC) for the entire study period of prevalence and incidence were calculated. The significance level was set at 0.05. All statistical analyses were performed by using SAS statistical software, version 9.3.

### **Role of the sponsors**

The sponsor of the study, University of Nottingham and Chang Gung Memorial Hospital, had no role in study design, collection, analysis and interpretation of the data and the preparation, review or approval of the paper.

## Results

### Prevalence and incidence in 2012

Of 4,634,974 eligible individuals in 2012, 115,608 prevalent cases of gout were identified, giving a prevalence of 2.49% (95% CI, 2.48%–2.51%). Men had a significantly higher prevalence of gout (3.97%; 95% CI, 3.96%–4.00%) than women (1.05%; 95% CI, 1.04%–1.06%). This gender difference was observed in all ages with a male to female ratio of 1.5 in individuals younger than 20 years, peaking at 11.2 in those aged 35-39 years bands and then decreasing to 2.5 for those older than 90 years. Gout was rare in people younger than 20 years (5.11 cases per 100,000 individuals) and it increased with age thereafter. In both men and women, the prevalence plateaued after the age of 80 years (figure 1a). In the adult population aged 20 years of more, the prevalence of gout (95% CI) was 3.22% (3.20%–3.23%) in overall population, 5.17% (5.14%–5.20%) in men and 1.34% (1.33%–1.36%) in women.

There were a total of 4,159,043 person-years of follow-up in this year during which 7,343 incident cases of gout were identified (overall incidence 1.77 [95% CI, 1.73–1.81] per 1000 person-years). Men had a higher incidence of gout (2.58 [95% CI, 2.51–2.65] per 1000 person-year) than women (0.99 [95% CI, 0.95–1.04]) per 1000 person year). As shown in figure 1b, incidence of gout was greatest in people aged 80-84 years in both men and women. The male to female ratio widened from the lowest in individuals younger than 20 years (1.2) to the a peak of 15.4 in those aged 30-34 years and thereafter the difference narrowed down. In adult population, the incidence of gout (95% CI) was 2.26 (2.21–2.31) per 1,000 person-years in the adult population, 3.50 (3.26–3.44) per 1,000 person-years in men and 1.25 (1.20–1.31) per 1,000 person-years in women.

## Prevalence and incidence of gout between 1997 and 2012

Table 1 shows the temporal trends in prevalence and incidence of gout from 1997 to 2012. In general, both crude and standardised estimates increased over time during this period. The standardised estimates were slightly higher than the crude ones, accounting for the fact that the average length of data contribution was higher in 2012 than 1997.

The standardised prevalence of gout increased 63.9% over the study period. On average, the standardised prevalence increased 4.2% (95% CI, 3.9%–4.5%) per year, suggesting the prevalence of gout in UK was increasing over the study period. Furthermore, there were two joinpoints at 2000 and 2008 with respective APCs of 1.3 (0.5–2.1), 4.6 (4.3–4.9) and 3.3 (2.8–3.8) for segment 1997–2000, 2000–2008 and 2008–2012 respectively. As Figure 2a shows, the temporal trend of prevalence in men and women was not parallel ( $p < 0.001$ ). On average, prevalence in women increased 4.6% (95% CI, 4.3%–5.0%) and was slightly higher than in men (4.1% [95% CI, 3.7%–4.4%]). However, the male-to-female ratio was only slightly narrowed from 4.8 fold in 1997 to 4.3 fold in 2012.

The standardised incidence also increased significantly (29.6%) during the study. On average, the incidence of gout increased 1.5% (95% CI, 1.1%–1.9%) per year and there was only one join point (2003). The annual change of incidence increased 3.8% (95% CI, 2.7%–4.9%) per year during the period between 1997 and 2003 but the incidence reached a plateau afterwards, with an annual change of 0.2 (95% CI, -0.4 to 0.9;  $p = 0.45$ ). Figure 2b shows a very similar trend of gout incidence in men and women ( $p = 0.171$ ), albeit a slightly higher average annual change in women (2.0%, 95% CI, 1.3%–2.7%) than in men (1.5%, 95% CI, 0.9–2.0%). The male to female ratio in incidence slightly reduced from 3.4 in 1997 to 3.0 in 2012.

### **Geographic variation in 2012**

Both prevalence and incidence of gout were not uniform throughout the UK. As shown in Figure 3, the standardised prevalence (95% CI) of gout was highest in the North East (3.11% [3.00%–3.23%]) and Wales (2.98% [2.93–3.02]). Regions with the lowest prevalence of gout were Scotland (2.02% [1.98%–2.06%]) and Northern Ireland (2.15% [2.07–2.22]). The East of England and Northern Ireland were the regions with the lowest standardised incidence (95% CI) of gout (1.50 [1.37–1.65], 1.57 [1.45–1.69] per 1000 patient-years respectively), while Wales and the North East had the highest incidence (2.28 [95% CI, 2.13–2.43] and 2.17 [95% CI, 1.85–2.54] per 1,000 patient-years respectively).

### **Management of gout between 1997 and 2012**

Among prevalent gout patients in 2012, approximately half were being consulted specifically for gout or being treated by ULT (48.48%; 95% CI, 48.08%–48.89%) and only one-third were being treated with ULT (37.63%, 95% CI, 37.28%–38.99%). As shown in Figure 4a, the percentage of patients being consulted for gout or treated by ULT remained poor and almost constant during the study period, with a APC (95% CI) of -0.3% (-0.4% to -0.2%). Similarly, the percentage of patients being treated by ULT has not changed, with an APC of -0.1% (-0.2% to 0.1%).

In 2012, only 18.6% (95% CI, 17.6%–19.6%) of incident gout patients received ULT within 6 months and approximately one in four were treated within 12 months of diagnosis (27.3%; 95% CI, 26.1%–28.5%). As Figure 4b shows, the percentage of patients receiving ULT within 6 and 12 months changed only marginally during the study period with APCs (95% CI) of -1.0% (-2.1 to 0.2;  $p = 0.100$ ) and -0.8 (-1.6 to 0.1;  $p = 0.07$ ), suggesting that the management of incident gout patients has remained essentially the same over the past 16 years.

### **Adherence to urate-lowering treatment**

Among ULT-treated patients in 2012 (n = 49395), 39.66% (95% CI, 39.11%–40.22%) were adherent to treatment. Partially adherent and non-adherent patients comprised 42.84% (95% CI, 42.27%–43.42%) and 17.50 (95% CI, 17.13%–17.87%), respectively. In contrast to the percentage of patients receiving ULT, patient adherence to ULT improved in the past 16 years (figure 5). Overall, the percentage of adherent patients improved from 28.28% (95% CI, 27.33%–29.26%) in 1997 to 39.66% (95% CI, 39.11%–40.22%) in 2012. The average APC was 2.0 (95% CI, 1.5–2.5). Joinpoints were attributed to 2002 and 2008, with APCs (95% CIs) of 4.5 (2.6–6.4) for 1997–2002, 2.2 (1.0–3.4) for 2002–2008 and 0.0 (-1.3 to 1.4) for 2008–2012. In contrast, the percentage of partially adherent and non-adherent patients reduced 13.0% and 22.0% respectively.

## Discussion

This study demonstrates that the burden of gout in the UK is higher than previously thought, with approximately one in 40 adults being affected. Furthermore the prevalence of gout has continued to increase from 1997 to 2012 despite a stabilised incidence after 2005. Gout is not distributed uniformly within the UK, the highest prevalence and incidence of gout being in the North East and Wales. Unfortunately, despite this rising prevalence and the publication of European[25] and UK[26] guidelines in 2006 and 2007 respectively, the management of gout appears to be more than suboptimal with only one in three prevalent patients receiving ULT and only one in four newly diagnosed patients received ULT within one year of diagnosis. Although patient adherence to ULT has improved in the past decade this still remains poor.

Early studies showed an increase in gout prevalence in the UK up until 1999, when a nationwide study by Mikuls et al. using the GPRD reported an overall prevalence of 1.39%.[18] Using the IMD analyser in the period 2000–2005, Annemans et al. reported an identical prevalence of 1.4% suggesting that gout prevalence may have reached a plateau.[19] In contrast, our prevalence estimates were slightly higher during the period 1999–2005 and continued to increase throughout the study period. We consider this disparity to primarily result from different degrees of identification of clinically silent patients, whose identification depends on a period of data contribution that is long enough to include a prior gout event. However, it is difficult to determine how many years of observation are sufficient to exclude this bias since data on length of asymptomatic inter-critical gout period are sparse. Only one case series in 1961 reported that the length of inter-critical periods was less than 1 year in 62%, 1-5 years in 27%, 6-10 years in 4% and over 10 years in 7% of 614 patients.[27] Therefore,



we did not set a minimal length of data contribution but instead utilised direct standardisation considering age, sex and length of data contribution to circumvent the incomplete identification of inter-critical gout patients. Therefore, studies that have not examined prior data contribution will have underestimated the prevalence of gout in the UK. When this bias is avoided it is apparent that the standardised prevalence of gout has risen since 1997. In addition, the prevalence of gout in the UK is higher than recent estimates in other European countries, specifically 1.4% in Germany [19] and 0.91% in Italy.[28]

Very few studies have addressed the incidence of gout. Using data from the UK Second and Third National Studies of Morbidity in General Practice in the UK, overall gout incidence was estimated to be 1.4 per 1000 person-years in 1981.[29] Incidence estimates based on the GPRD ranged from 1.19 to 1.80 per 1,000 person-years in the period 1990–1999[18] and those based on the Royal College of General Practitioners Weekly Returns Service (WRS) ranged from 1.12 and 1.35 per 1,000 population between 1994 and 2007. Another study using the THIN database reported an incidence of 2.68 per 1,000 person-years in the adult population in the period 2000–2007.[30] Our estimates of incidence in general fall within these previous reported ranges. However, we found that the incidence of gout has increased by more than one quarter during the study period. Although it reached a plateau after 2004, it has shown no signs of subsequent reduction, a finding echoed by our observations of an increasing prevalence. Therefore gout will remain a commonly encountered disorder and the prevalence may even continue to rise in the near future.

In addition to temporal changes we also documented clear evidence for regional variations in gout. The patterns for prevalence and incidence were similar, with the North East and Wales having the highest estimates for both. Regional variation within the UK has been noted

previously in just two studies. In a survey in 1975 Currie et al. reported a higher prevalence of gout in England than in Wales[14] and in 1982 Gardner et al. reported a lower prevalence (3.9%) in adults over age 45 in Ipswich in Suffolk than in the two more northern towns of Wakefield (4.5%) and Preston (4.9%).[15] To the best of our knowledge, there are no previous reports of geographical variation in incidence of gout in the UK. The reasons for current geographic variation in gout most likely relate to differences in socioeconomic status, life-style and nutrition and although gout historically was considered a disease of affluence, the converse may now be true. The UK morbidity statistics from general practice (1970-71) reported that people with non-manual skilled occupations had the highest whereas professional occupations had the lowest standardised consulting ratio for gout (133 vs. 79)[31] and Gardner's study found a lower prevalence of gout in the town with the most favourable socioeconomic status.[15] In addition, a recent New Zealand study also found that the least deprived people had the lowest risk of gout.[32] However, further studies are needed to explore the reasons for current variation by socioeconomic group and region.

Regardless of the increasing prevalence and incidence of gout in the UK, the management of the disease remains poor. We found that throughout 1997–2012 only around one third of people with prevalent gout were prescribed ULT. The management for incident gout patients also remained unchanged with only a quarter to a third of patients being treated with ULT within one year of diagnosis. This shows no significant change in overall usage of ULT from Mikuls' estimates of 25.3%-29.5% from 1990 to 1999[18]. Apart from under-prescribing of ULT, Mikuls et al identified inappropriate prescribing of ULT in one quarter to one half of those people in whom quality indicators could be assessed[33] and a more recent study also demonstrated suboptimal care in many aspects of gout management.[34] Collectively, these

results reflect widespread lack of knowledge of gout and poor alignment with current recommendations of best practice within the UK.[35-37] Although guidelines do not explicitly advise discussion of ULT with every gout patient around the time of diagnosis, the majority of patients will have recommended specific indications (e.g.further attacks,[27] renal impairment,[38] required chronic diuretic use,[38] nephrolithiasis,[39] peripheral joint damage or tophi[40]) at diagnosis or within 6-12 months. Furthermore, increasingly the trend is towards early treatment with ULT to prevent people developing further crystal deposition and complications such as subcutaneous tophi and joint damage.[37] Best practice requires full patient information concerning gout and its treatment [25, 26, 37] and in one recent UK study, when patients received this 100% wished to receive ULT.[36, 37] Being that gout is the only chronic arthritis for which there is “curative” treatment, the use of ULT would seem a useful indicator of standard of care.[37]

We also found that only approximately 40% of treated patients in 2012 adhered to ULT. This accords with a recent review of six studies which reported that only 18% to 44% of patients with gout adhere to ULT.[41] Such poor adherence to ULT has long been recognised, one review finding adherence in gout patients to be the worst of seven chronic diseases requiring chronic medication.[42] Nevertheless, we did find an encouraging signal of a 40% improvement in percentage of adherent patients from 1997 to 2012. Although previous studies largely blame patients for poor adherence,[41, 43] a recent study indicated that appropriate patient education can effectively maintain high adherence to ULT and achieve therapeutic target in nine out of ten gout patients.[44] Therefore, as with low rates of ULT prescription, it is likely that the fault lies more with the health practitioners than with the patients.[37] There are many recognised barriers to care of gout, both in patients and

practitioners, but practitioner education seems the first prerequisite to address these problems.

There are several limitations to the study. Firstly, we based our case definition on diagnosis by the general practitioners, rather than according to American College of Rheumatology[45] or Rome[46] classification criteria or to the 'gold standard' of urate crystal identification and this may lead to misclassification bias. However, the validity of gout diagnosis in the CPRD has been investigated and found to be high.[23] Secondly, we based our adherence estimation on PDC, which is generally believed to be more conservative than the more commonly used measure of medication possession ratio. We assumed patients took all prescribed pills since calculation of PDC relies on records of prescription refills, but this assumption may not hold true and may have led to an overestimation of adherence.

In conclusion, both the prevalence and incidence of gout have risen in the past 16 years and are the highest reported within Europe. However, despite being the commonest inflammatory arthritis the suboptimal management of gout continues unchanged, with only a minority of patients receiving ULT and new patients not being treated in a timely fashion. Although somewhat improved patient adherence to ULT remains poor. It is apparent that educational initiatives to improve practitioner knowledge, interest and standard of care of the only “curable” form of inflammatory arthritis are urgently required.

## **Acknowledgement**

We would like to thank the University of Nottingham and Chang Gung Memorial Hospital (project CMRPG3A0623) for financially supported this research. Both sponsors of the study had no role in design and conduct of the study; collection, management, analysis, and

interpretation of the data; and preparation, review, or approval of the manuscript.

## **Licence for Publication**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in ARD and any other BMJPG products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

## **Competing interest**

The authors have no competing interest to declare.

## **Author contributions**

CFK and WZ had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CFK, WZ and MD conceived and designed the study. CFK and WZ acquired the data. CFK, MJG, and WZ performed and supervised the statistical analysis. CFK, MJG, CM, WZ and MD analysed and interpreted the data. CFK and WZ drafted the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content. WZ, MJG and MD supervised the study.

## **Data sharing**

Additional data and statistical codes are available on request from the corresponding author at [weiya.zhang@nottingham.ac.uk](mailto:weiya.zhang@nottingham.ac.uk).



## References

1. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I, Therapeutics ESCfCSI. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis* 2006;65:1301-1311.
2. Ab. Usbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. *J Clin Epidemiol* 1988;41:237-242.
3. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. *Arthritis Rheum* 2006;54:2688-2696.
4. Sheane BJ, Cunnane G. Tophaceous gout and chronic kidney disease. *J Clin Rheumatol* 2007;13:293.
5. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. *Circulation* 2007;116:894-900.
6. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, Group MR. Long-term cardiovascular mortality among middle-aged men with gout. *Arch Intern Med* 2008;168:1104-1110.
7. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Lin CM, Chen HW, Yu KH. Gout: an independent risk factor for all-cause and cardiovascular mortality. *Rheumatology (Oxford)* 2010;49:141-146.
8. Terkeltaub R. Update on gout: new therapeutic strategies and options. *Nat Rev Rheumatol* 2010;6:30-38.
9. Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PD. Appropriateness of medication selection for older persons in an urban academic emergency department. *Academic Emergency Medicine* 1999;6:1232-1242.
10. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). *Rheumatology (Oxford)* 2005;44:1038-1042.
11. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang YQ. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. *Journal of Rheumatology* 2006;33:104-109.
12. Roddy E, Zhang WY, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. *Ann Rheum Dis* 2007;66:1311-1315.
13. Badley EM, Meyrick JS, Wood PH. Gout and serum uric acid levels in the Cotswolds. *Rheumatol Rehabil* 1978;17:133-142.
14. Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. *Ann Rheum Dis* 1979;38:101-106.
15. Gardner MJ, Power C, Barker DJ, Padday R. The prevalence of gout in three English towns. *Int J Epidemiol* 1982;11:71-75.
16. Steven MM. Prevalence of chronic arthritis in four geographical areas of the Scottish Highlands. *Ann Rheum Dis* 1992;51:186-194.
17. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. *J Clin Epidemiol* 1995;48:1153-1158.
18. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Jr., Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. *Ann Rheum Dis* 2005;64:267-272.
19. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. *Ann Rheum Dis* 2008;67:960-966.
20. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. *Ann Rheum Dis* 2009;68:1728-1733.
21. Cea Soriano L, Rothenbacher D, Choi HK, Garcia Rodriguez LA. Contemporary epidemiology of

gout in the UK general population. *Arthritis Res Ther* 2011;13:R39.

22. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Clin Pharmacol* 2010;69:4-14.
23. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. *Br J Clin Pharmacol* 1997;44:175-178.
24. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000;19:335-351.
25. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCSIT). *Ann Rheum Dis* 2006;65:1312-1324.
26. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl JR, Hingorani A, Jaques R, Nuki G, Rheumatology BS, R BHP, SGAWG. British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout. *Rheumatology (Oxford)* 2007;46:1372-1374.
27. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. *Ann Intern Med* 1961;55:179-192.
28. Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, Caputi AP, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. *Ann Rheum Dis* 2013;72:694-700.
29. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases--4. Gout. *Br J Rheumatol* 1990;29:485-488.
30. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. *Ann Rheum Dis* 2009;68:1728-1733.
31. Great Britain. Office of Population C, Surveys, Royal College of General P, Great Britain. Dept. of H, Social S. Morbidity statistics from general practice 1970-71 : socio-economic analyses. London: H.M.S.O., 1982.
32. Jackson G, Wright C, Thornley S, Taylor WJ, Te Karu L, Gow PJ, Arroll B, Gribben B, Dalbeth N, Winnard D. Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. *Rheumatology (Oxford)* 2012;51:1820-1824.
33. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). *Rheumatology (Oxford)* 2005;44:1038-1042.
34. Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. *Rheumatology (Oxford)* 2010;49:105-111.
35. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. *Ann Rheum Dis* 2012;71:1490-1495.
36. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. *Ann Rheum Dis* 2013;72:826-830.
37. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T. Gout: why is this curable disease so seldom cured? *Ann Rheum Dis* 2012;71:1765-1770.
38. Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. *BMJ* 2012;344:d8190.
39. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. *Kidney Int* 2003;64:1022-1026.
40. McGill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. *J Rheumatol* 1991;18:1042-1045.
41. Reach G. Treatment adherence in patients with gout. *Joint Bone Spine* 2011;78:456-459.
42. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy* 2008;28:437-443.
43. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns



in a large cohort of older adults. *Ann Rheum Dis* 2008;67:609-613.

44. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. *Ann Rheum Dis* 2013;72:826-830.

45. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum* 1977;20:895-900.

46. KellgrenJH J, BallJ, editors. The epidemiology of chronic rheumatism: Oxford: Blackwell;, 1963.